UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
NCT00574080
Terminated
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2017
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
NCT01660750
Completed
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex) prior to autologous stem cell transplant (ASCT) in patients with newly diagnosed transplant eligible multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2017
Locations: Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
CD123 Redirected Autologous T Cells for AML
NCT02623582
Terminated
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2017
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Relapsed or Refractory Acute Myeloid Leukemia
Register for Updates
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
NCT01265901
Completed
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib. Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2017
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +105 locations
Conditions: Metastatic Renal Cell Carcinoma
Register for Updates
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00376961
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Givin... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/03/2017
Locations: Alaska Regional Hospital Cancer Center, Anchorage, Alaska +146 locations
Conditions: Lymphoma
Register for Updates
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
NCT00242996
Completed
RATIONALE: Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, and chemotherapy, such as cyclophosphamide, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored for peripheral stem cell transplant. Giving chemotherapy, such as carmustine, etoposide, and cyclophosphamide, before transplant stops the growth of cancer cells by stopping them from dividing or killing them. The stem cells are then returned to the p... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/27/2017
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Lymphoma
Register for Updates
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
NCT00281879
Terminated
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells can make an immune response against the body's normal cells. Methotrexate, cyclosporine, tacroli... Read More
Gender:
ALL
Ages:
60 years and below
Trial Updated:
09/25/2017
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Register for Updates
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
NCT00003659
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine plus high-dose cyclophosphamide and rituximab in treating patients who have previously untreated chronic lymphocy... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/22/2017
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Leukemia
Register for Updates
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
NCT00006184
Completed
Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an incurable disease with a median survival of approximately 30 months. Allogeneic stem cell transplantation (SCT) results in a high percentage of complete remissions, but it can be associated with significant treatment-related mortality, which has been primarily attribu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/19/2017
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Multiple Myeloma
Register for Updates
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
NCT00899847
Completed
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/19/2017
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Register for Updates
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NCT00408408
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the g... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
09/12/2017
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +441 locations
Conditions: Breast Cancer
Register for Updates
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01689987
Completed
This phase I trial studies the side effects and best dose of hydroxychloroquine when given together with cyclophosphamide, dexamethasone, and sirolimus in treating patients with multiple myeloma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as hydroxychloroquine, may stimulate the immune system in different ways and stop cancer cells from growing. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2017
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates